Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Lindsley

Showing results (351-360 of 570) with videos related to

Pageof 57
Sort By:
ACS Chemical Biology|May 28, 2011
Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133Hao-Ran Wang, Meng Wu, Haibo Yu, et al.
ACS Chemical Neuroscience|September 20, 2011
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addictionCraig W Lindsley, Brittney S Bates, Usha N Menon, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonistsDouglas L Orsi, Andrew S Felts, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Journal of Medical Genetics|December 6, 2018
Kabuki syndrome: international consensus diagnostic criteriaMargaret P Adam, Siddharth Banka, Hans T Bjornsson, et al.
Cancer Research|May 14, 2009
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancerTodd W Miller, Marianela Pérez-Torres, Archana Narasanna, et al.
Assay and Drug Development Technologies|February 17, 2026
Identification of Kir2.1 Inhibitors from a High-Throughput ScreenJacob L Bouchard, Pedro de Andrade Horn, Yu Nishio, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Science Signaling|November 15, 2022
M<sub>1</sub> muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative diseaseLouis Dwomoh, Mario Rossi, Miriam Scarpa, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Pageof 57

Showing results (351-360 of 570) with videos related to

Sort By:
Pageof 57
ACS Chemical Biology|May 28, 2011
Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133Hao-Ran Wang, Meng Wu, Haibo Yu, et al.
ACS Chemical Neuroscience|September 20, 2011
(3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addictionCraig W Lindsley, Brittney S Bates, Usha N Menon, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2022
Discovery of a potent M<sub>5</sub> antagonist with improved clearance profile. Part 2: Pyrrolidine amide-based antagonistsDouglas L Orsi, Andrew S Felts, Alice L Rodriguez, et al.
ACS Medicinal Chemistry Letters|January 12, 2013
Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic ActivityYa Zhou, Jason T Manka, Alice L Rodriguez, et al.
Journal of Medical Genetics|December 6, 2018
Kabuki syndrome: international consensus diagnostic criteriaMargaret P Adam, Siddharth Banka, Hans T Bjornsson, et al.
Cancer Research|May 14, 2009
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancerTodd W Miller, Marianela Pérez-Torres, Archana Narasanna, et al.
Assay and Drug Development Technologies|February 17, 2026
Identification of Kir2.1 Inhibitors from a High-Throughput ScreenJacob L Bouchard, Pedro de Andrade Horn, Yu Nishio, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Science Signaling|November 15, 2022
M<sub>1</sub> muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative diseaseLouis Dwomoh, Mario Rossi, Miriam Scarpa, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Pageof 57